Хуудас 1 -аас 48 үр дүн
This invention relates to new aryloxy indole derivatives as pharmaceuticals which are useful for the treatment in mammals of diseases affected by disorders of the serotonin-affected neurological systems, such as depression, anxiety, panic disorder, obsessive-compulsive disorder, sleep disorders,
CROSS-REFERENCES TO RELATED APPLICATION
This patent application claims the benefit of priority under 35 U.S.C. .sctn.119 from Korean Patent Application No. 10-2008-0033284 filed Apr. 10, 2008, the contents of which are incorporated herein by reference.
TECHNICAL FIELD
The present disclosure relates
The present invention relates to cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives thereof, which are serotonin 5-hydroxytryptamine 2.sub.c (5HT.sub.2c) receptor agonists useful for the treatment of central nervous system disorders including, but not limited to, obsessive-compulsive
The present invention relates to cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives thereof, which are serotonin 5-hydroxytryptamine 2.sub.C (5HT.sub.2C) receptor agonists useful for the treatment of central nervous system disorders including, but not limited to, obsessive-compulsive
FIELD OF THE INVENTION
The present invention relates to therapeutic methods for the treatment and prevention of various disease conditions using heterocyclic compounds. In addition, the invention relates to methods of modulating processes mediated by excitatory amino acid receptors. The invention
BACKGROUND OF THE INVENTION
The present invention relates to novel heterocyclic carboxamides to intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the present invention include selective agonists and antagonists of
BACKGROUND OF THE INVENTION
The neurotransmitter/hormone serotonin (5-hydroxytryptamine, 5-HT) regulates many physiological processes via a group of at least 14 distinct receptors that are organized into 7 subfamilies (Hoyer, D., et al., Pharmacol. Rev., 46, 1994). The 5-HT.sub.2 subfamily is
BACKGROUND OF THE INVENTION
The neurotransmitter/hormone serotonin (5-hydroxytryptamine, 5-HT) regulates many physiological processes via a group of at least 14 distinct receptors that are organized into 7 subfamilies (Hoyer, D., et al., Pharmacol. Rev., 46, 1994). The 5-HT.sub.2 subfamily is
BACKGROUND
The neurotransmitter/hormone serotonin (5-hydroxytryptamine, 5-HT) regulates many physiological processes via a group of at least 14 distinct receptors that are organized into 7 subfamilies (Hoyer, D., et al., Pharmacol. Rev., 46, 1994). The 5-HT.sub.2 subfamily is composed of the
CROSS REFERENCE TO RELATED APPLICATIONS
This is a National Stage of International Application No. PCT/JP2009/067441 filed Sep. 30, 2009, claiming priority based on Japanese Patent Application No. 2008-257072 filed Oct. 2, 2008, the contents of all of which are incorporated herein by reference in
The present invention relates to the use of 1-[4-(5-cyanoindol-3-yl)butyl[-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof, for the manufacture of a medicament for the treatment of sub-type anxiety
The present invention relates to the use of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof, for the manufacture of a medicament for the treatment of sub-type anxiety
The present invention relates to the use of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine or a physiologically acceptable salt thereof, for the manufacture of a medicament for the treatment of sub-type anxiety
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention is directed to inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, the chemical synthesis thereof, and the medical use of such compounds for the treatment
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention is directed to inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, the chemical synthesis thereof, and the medical use of such compounds for the treatment